FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits

July 1, 2021
12:51 pm

FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits

At this writing three members of the FDA Advisory Committee have chosen to resign in protest over the Food and Drug Administrations decision to approve aducanumab for the treatment of mild cognitive impairment. Their decision to resign is commendable for…

Click here to view the original article.

Global, MarketWatch

Share this article

Handling $50M in ARC Perpetual Volume

March 1, 2026

Crypto News: Pepeto Announces $7.39M Presale Fast As Bitcoin Targets $250,000 And Ethereum Targets $6,000 After The Death Of Khamenei

March 1, 2026

South Korean Police Lose Seized Crypto By Posting Password Online

March 1, 2026

Matt Hougan: Bitcoin ETFs could reach a trillion dollars, institutions see market dips as opportunities, and wealth managers are gradually gaining Bitcoin access

March 1, 2026

Blockchain Intelligence Firm TRM Labs Focuses On Legal Frameworks For Crypto Sector

March 1, 2026

Bitcoin Sell-Off Fears Rise as War Threatens Iran’s BTC Mining Operations

March 1, 2026

RIPPLE PUSHES BANKS TO ACT — Clarity Act Could Reshape Crypto Rules

March 1, 2026

Crypto investment cons now run like call centers and the DOJ $580M haul shows where the money pools

March 1, 2026